SG11201911617SA - T cells with reduced surface fucosylation and methods of making and using the same - Google Patents

T cells with reduced surface fucosylation and methods of making and using the same

Info

Publication number
SG11201911617SA
SG11201911617SA SG11201911617SA SG11201911617SA SG11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA
Authority
SG
Singapore
Prior art keywords
cells
making
methods
same
reduced surface
Prior art date
Application number
SG11201911617SA
Other languages
English (en)
Inventor
Nicole Okeley
Jessica Field
Shyra Gardai
Ryan Heiser
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201911617SA publication Critical patent/SG11201911617SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
SG11201911617SA 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same SG11201911617SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516536P 2017-06-07 2017-06-07
PCT/US2018/036067 WO2018226701A1 (fr) 2017-06-07 2018-06-05 Lymphocytes t à fucosylation de surface réduite et procédés de production et d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
SG11201911617SA true SG11201911617SA (en) 2020-01-30

Family

ID=62751563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911617SA SG11201911617SA (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Country Status (16)

Country Link
US (2) US11891644B2 (fr)
EP (1) EP3634427A1 (fr)
JP (1) JP7245177B2 (fr)
KR (1) KR20200015580A (fr)
CN (1) CN110740734A (fr)
AU (1) AU2018282225B2 (fr)
BR (1) BR112019025775A2 (fr)
CA (1) CA3065524A1 (fr)
EA (1) EA201992875A1 (fr)
IL (1) IL271012B2 (fr)
MA (1) MA50865A (fr)
MX (1) MX2019014584A (fr)
SG (1) SG11201911617SA (fr)
TW (1) TW201903144A (fr)
WO (1) WO2018226701A1 (fr)
ZA (1) ZA201907623B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034774A1 (fr) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation et immunomodulation dans le cancer
WO2022221766A1 (fr) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation et modulation immunitaire dans le cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US9504702B2 (en) * 2010-08-05 2016-11-29 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
KR20200032763A (ko) 2014-02-04 2020-03-26 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
CN106459917B (zh) 2014-04-23 2021-03-09 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
MA40595A (fr) 2014-09-09 2021-05-26 Unum Therapeutics Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
JP7068820B2 (ja) 2014-12-03 2022-05-17 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための方法および組成物
US20170136063A1 (en) 2015-10-20 2017-05-18 Kite Pharma, Inc. Methods of Preparing T Cells for T Cell Therapy
CN108289903B (zh) 2015-12-04 2021-08-03 西雅图基因公司 与检验点抑制剂联合使用2-脱氧-2-氟-l-岩藻糖的癌症治疗

Also Published As

Publication number Publication date
MX2019014584A (es) 2020-02-07
AU2018282225B2 (en) 2024-06-13
US20200149082A1 (en) 2020-05-14
EP3634427A1 (fr) 2020-04-15
AU2018282225A1 (en) 2019-12-12
KR20200015580A (ko) 2020-02-12
MA50865A (fr) 2020-04-15
US20240117400A1 (en) 2024-04-11
TW201903144A (zh) 2019-01-16
ZA201907623B (en) 2024-04-24
US11891644B2 (en) 2024-02-06
IL271012B2 (en) 2023-12-01
BR112019025775A2 (pt) 2020-06-23
CA3065524A1 (fr) 2018-12-13
JP2020523014A (ja) 2020-08-06
IL271012B1 (en) 2023-08-01
WO2018226701A1 (fr) 2018-12-13
EA201992875A1 (ru) 2020-03-25
JP7245177B2 (ja) 2023-03-23
IL271012A (en) 2020-01-30
CN110740734A (zh) 2020-01-31

Similar Documents

Publication Publication Date Title
HK1250481A1 (zh) 經過修飾的t細胞及其製備和使用方法
IL262772A (en) Genetically engineered cells and methods for their preparation
EP3601528A4 (fr) Cellules et méthodes d'utilisation et de production de celles-ci
IL255801A (en) Liposomal nanoconstructs and methods of making and using the same
EP3231024A4 (fr) Cellule électrochimique et son procédé de fabrication
SG11202004116QA (en) T cell manufacturing compositions and methods
EP3024417A4 (fr) Greffon présentant une zone expansible et procédés de fabrication et d'utilisation du greffon
EP3093889B8 (fr) Cellule solaire et son procede de fabrication
EP3443608A4 (fr) Cellules électrochimiques à champs d'écoulement conçus et leurs procédés de fabrication
EP3327793C0 (fr) Cellule solaire et son procédé de fabrication
EP3374559A4 (fr) Non tissé présentant une résistance améliorée à l'abrasion et son procédé de fabrication
IL280240A (en) T-cells containing nef and methods for their production
EP3516127A4 (fr) Structure et son procédé de fabrication
HK1244512A1 (zh) 突變型smoothened及其使用方法
SG11201900459RA (en) Mg53 mutants, methods of making the same, and uses thereof
EP3538250A4 (fr) Structures comprenant des polyamines supportées et procédés de fabrication des polyamines supportées
EP3735303A4 (fr) Surfaces portantes hydrodynamiques et procédés
EP3096892A4 (fr) Substrats revêtus de nanotubes de carbone et leurs procédés de fabrication
EP3218477A4 (fr) Compositions et procédés permettant l'expression de polypeptides à la surface de cellules
IL250554A0 (en) Improved substrates that promote bone growth and methods of making them
EP3651606A4 (fr) Revêtements de pierres précieuses et procédés de fabrication et d'utilisation associés
EP3494217A4 (fr) Cellules exprimant la lmp-1 et leurs méthodes d'utilisation
EP3096742A4 (fr) Compositions et procédés de modification de la surface de cellules, et procédés d'utilisation
IL271012A (en) T cells with reduced surface fucosylation and methods for their preparation and use
EP3356418A4 (fr) Anticorps anti-podocalyxine et leurs méthodes d'utilisation